Status:
NOT_YET_RECRUITING
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Vaccine
Pneumococcal Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will...
Eligibility Criteria
Inclusion
- Healthy adult
Exclusion
- No prior history of pneumococcal vaccination
- No immunosuppressing medications or chronic diseases that affect immune function
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07135453
Start Date
January 1 2026
End Date
August 1 2026
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294